In a systematic review of 18 trials (16 network meta-analysed) of add-on therapy for persistent overactive bladder symptoms in α1-blocker-treated men with BPH, vibegron cut micturitions (−0.81/24 h) and urgency versus control; no clear advantage over mirabegron was shown.
Meta-analysisn = 18 trials
Yajima et al. Vibegron, mirabegron, and other add-on therapies for persistent overactive bladder symptoms in α1-blocker-treated men with benign prostatic hyperplasia: a systematic review and Bayesian network meta-analysis